Full-Time
Intern – Data Analytics
Posted on 3/20/2026
Impiricus
51-200 employees
Healthtech platform delivering point-of-care pharma updates
Compensation Overview
$25/hr
Remote in USA + 1 more
More locations: New York, NY, USA
Hybrid
Bachelor's
 Data & Analytics (1) |
|---|
Get referred to Impiricus
See people who can refer or advise you
- Currently pursuing or recently completed degree in Data Science, Statistics, Mathematics, Business Analytics, or a related STEM field.
- Strong proficiency in Excel or Google Sheets.
- Curious, analytical, and detail-oriented with strong problem-solving skills.
- Able to communicate insights through presentations, slides, or written summaries, translating complex data into clear and intuitive takeaways for internal teams and clients.
- Able to manage time effectively and work independently in a fast-paced environment.
- Analyze marketing campaign performance data and help track key metrics.
- Support list match validation and audience performance analysis.
- Build Excel- or spreadsheet-based reports and visual summaries for internal stakeholders.
- Work with Client Services and Engineering teams to support data requests and cross-team projects.
- Translate data findings into clear, actionable insights and recommendations.
- Help develop repeatable templates and processes for ongoing analytics needs.
- Experience with SQL or data visualization tools.
- Exposure to marketing, campaign, or performance data.
- Interest in or familiarity with the healthcare or biopharma industry.
Impiricus is a healthtech platform connecting healthcare providers with the latest pharmaceutical innovations. It works by leveraging a proprietary network of over 800,000 HCPs and delivering relevant information at the point of care through customized campaigns integrated with clients’ teams. It differentiates itself with a large, diverse network that includes low-see and no-see HCPs and by creating tailored campaigns that drive higher engagement. Its goal is to improve patient care by giving providers timely knowledge when they need it, while generating revenue from access to the HCP network and from developing and implementing engagement campaigns for pharmaceutical companies and healthcare organizations.
Company Size
51-200
Company Stage
Early VC
Total Funding
$4.6M
Headquarters
Atlanta, Georgia
Founded
2020
Get referred to Impiricus
See people who can refer or advise you
Simplify's Take
What believers are saying
- Impiricus claims a top-five pharma customer drove a $60 million lift.
- Inc. named Impiricus to its 2026 fastest-growing private companies list.
- The platform reached underserved physicians and launched Ascend for existing and new partners.
What critics are saying
- Large pharma can internalize HCP messaging, shrinking Impiricus' middleman role by 2027.
- Ascend's AI claims invite HIPAA, consent, and pharma-compliance scrutiny after launch.
- Revenue concentration in pharma marketing leaves Impiricus exposed if top clients cut budgets.
What makes Impiricus unique
- Impiricus combines 800,000+ opted-in HCPs with point-of-care pharma outreach.
- Ascend launched November 13, 2025, using agentic AI and tokenized data pipelines.
- Founded by physician CEO Osama Hashmi, it sells clinically framed engagement to pharma.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Unlimited Paid Time Off
401(k) Company Match
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 0%2 year growth
↑ 0%Impiricus, an Atlanta-based healthcare technology company, has been ranked No. 14 on the 2026 Inc. 5000 list of America's fastest-growing private companies. The company achieved an 11,691% growth rate over the three-year period. Founded by dermatologist Dr Osama Hashmi, Impiricus builds agentic AI infrastructure for healthcare commercialisation. The platform connects physicians with clinical resources and patient support in real time, aiming to accelerate patient access to treatment. The company was previously recognised as the fastest-growing company in North America on Deloitte's 2025 Technology Fast 500 list. The Inc. 5000 ranking is based on percentage revenue growth from 2022 to 2025, with this year's median growth rate at 130%.
Impiricus named No 14 on the 2026 Inc. 5000 List, the prestigious ranking of America's fastest-growing private companies. August 11, 2026, 11:00 GMT Company Recognized for 11,691% Three-Year Revenue Growth, Earning a Place Among the Nation's Most Successful Independent Businesses ATLANTA, GA, UNITED STATES, August 11, 2026 / EINPresswire.com / - Impiricus announced today that it has been ranked No. 14 on the 2026 Inc. 5000 list, the annual list of the fastest-growing private companies in America. The list is the most recognized ranking of the nation's most successful independent and entrepreneurial businesses, recognizing companies that have achieved remarkable growth while driving innovation, creating jobs, and shaping the future of the economy. Past honorees include companies such as Microsoft, Meta, Chobani, Oracle, and Patagonia. "Our 11,691% growth rate is a powerful validation of the problem we set out to solve: physicians need less noise and better access to the support that helps them care for patients," said Dr. Osama Hashmi, dermatologist, CEO and co-founder of Impiricus. "Earning the No. 14 spot on the Inc. 5000 reflects the trust we've built with physicians and life sciences leaders, and the extraordinary work of our team. Now we're taking that foundation even further, building agentic AI that turns physician engagement into real-time action and helps patients access treatment faster." Impiricus is building the agentic AI infrastructure for the next generation of healthcare commercialization, transforming physician engagement from information delivery to real-time clinical action. Its technology helps life sciences companies detect physician needs and connect HCPs with relevant clinical resources, patient support, and field teams at the exact time those resources can make a difference. Impiricus programs deliver measurable impact across major therapeutic areas, reaching white-space, digitally dark, and historically underserved physicians, helping accelerate patient access to treatment across the US. "Every company on the Inc. 5000 has a story of perseverance, smart decision making, and a refusal to sit still," says Mike Hofman, editor-in-chief of Inc. "Their growth reflects more than strong financial performance-it reflects creativity, resilience, and the customer focus required to build companies that make a lasting impact. We congratulate all honorees on this significant achievement." This year's Inc. 5000 recognizes a new class of companies redefining what growth looks like. From AI and advanced manufacturing to healthcare, consumer products, and professional services, these businesses are expanding their impact and proving that entrepreneurial ambition continues to fuel the U.S. economy. Among the 5,000 companies on the list, the median three-year revenue growth rate was 130%, and those companies have collectively added more than 627,208 jobs to the U.S. economy over the past three years. For the full Inc. 5000 list, honoree company profiles, and a searchable database by industry and location, please visit: www.inc.com/inc5000. Inc. 5000 List Methodology Companies on the 2026 Inc. 5000 are ranked according to percentage revenue growth from 2022 to 2025. To qualify, companies must have been founded and generating revenue by March 31, 2022. They must be U.S.-based, privately held, for-profit, and independent - not subsidiaries or divisions of other companies - as of December 31, 2025. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2022 is $100,000; the minimum for 2025 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. About Impiricus Impiricus is the first Agentic Commercialization Platform for healthcare. Founded by a practicing physician and a senior pharmaceutical executive, Impiricus is transforming how life sciences companies support physicians while accelerating patient access to life-saving treatments. Powered by the largest opted-in network of healthcare providers, its agentic AI platform delivers the right clinical resources, support, and connections exactly when and where physicians need them. Recognized by Deloitte as the #1 fastest-growing company in North America on the 2025 Technology Fast 500(TM), Impiricus provides the agentic AI infrastructure that transforms healthcare commercialization from information delivery to real-time clinical action. For more information, visit www.impiricus.com. About Inc. Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit www.inc.com. Yilan Yang Impiricus +1 617-485-6582 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above. You just read: August 11, 2026, 11:00 GMT EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above. Yilan Yang +1 617-485-6582
Mike Gelber, Chief Product Officer at Impiricus, named to MM+M's 40 Under 40 list. NEW YORK, NY - December 4, 2025 - MM+M has announced its seventh class of 40 Under 40 honorees, recognizing Mike Gelber, Chief Product Officer at Impiricus, the #1 fastest growing company in North America according to Deloitte. Gelber is honored for pioneering the future of ethical physician-pharma collaboration through the launch of Impiricus Ascend, an AI-powered communication platform that is fundamentally changing how healthcare professionals (HCPs) access critical resources. The MM+M 40 Under 40 list celebrates young leaders whose strategic thinking and digital facility contribute significantly to the healthcare industry's growth. "The individuals on the list are laying the foundation upon which the future of this industry will be built. They are creating a more equitable, inclusive landscape that will help pharma and biotech companies reach all patient populations," said MM+M editor-in-chief Jameson Fleming. Mike Gelber is the product visionary behind Ascend, Impiricus' flagship platform that resolves the physician pain point of information overload and accelerates patient access to care. Ascend is the solution for meeting HCPs where they are, cutting through the noise with personalized, efficient, and ethical pharma resource delivery. The platform is powered by proprietary AI models trained on over four billion HCP data points. Ascend leverages a unique, agentic AI delivery system with secure, tokenized data pipelines to amplify access to pharma resources for underserved physicians. This secure mobile-first experience allows physicians to connect with a representative in real-time and access essential resources like samples, treatment information, and dosing calculators. "Mike Gelber's dedication to AI innovation for ethical, HCP engagement is transforming how the pharma industry supports providers. Physicians report that these connections are helping patients access critical medications faster without the time burden of the traditional pharma model," said Dr. Osama Hashmi, Dermatologist, CEO and Co-founder of Impiricus. Impiricus has now been named the #1 fastest growing company in North America by the Deloitte Fast 500. Impiricus is the first and only AI-powered HCP Engagement Engine. Founded by a practicing physician and a senior pharmaceutical executive, Impiricus was created to transform how life sciences companies support physicians. Impiricus, Inc. ethically connect HCPs to pharma resources, reduce go-to-market costs and accelerate patient access to the treatments they need. With its unique access to the largest opted-in network of HCPs, their insights, and clinical expertise, Impiricus, Inc. is the leading provider of AI technology and real-time channels that life science companies need to deliver clear, reliable, and evidence-based resources directly into the hands of HCPs. Guided by a council of 2000+ trusted HCP advisors, Impiricus, Inc. ensure every interaction is clinically meaningful, ethically grounded and leads to better patient care. Read its content. News and insights. Mike Gelber, Chief Product Officer at Impiricus, named to MM+M's 40 Under... NEW YORK, NY - December 4, 2025 - MM+M has announced its... Deloitte unveils 2025 North America technology Fast 500(TM) rankings. NEW YORK, Nov. 19, 2025 /PRNewswire/ - Deloitte today released its "North... Impiricus launches Ascend, an AI platform to ethically connect physicians and pharma. Today's healthcare environment is marked by rapid drug advancements, evolving patient expectations,...
Impiricus launches ascend, an AI platform to ethically connect physicians and pharma. News provided by. Ascend sets a new standard in physician support through precision-tailored new resources to give patients faster, more reliable access to the treatments they need. ATLANTA, Nov. 13, 2025 /PRNewswire/ - Impiricus, a platform that connects healthcare providers with pharmaceutical and life sciences companies for equitable access to resources and improved patient care, today announced the launch of Impiricus Ascend, an AI-powered communication platform that ethically connects physicians to pharma resources. Physicians today face an overload of pharmaceutical outreach and information across multiple channels, creating a need to meet HCPs where they are for a more efficient, personalized solution. With Ascend, physicians are able to cut through the noise and act immediately on tailored, patient-focused resources that are aligned with their preferences and schedules. This approach ensures a new level of clinical support, reduced go-to-market costs and accelerated patient access to the needed treatments. Built on Impiricus' proprietary AI models trained on over four billion healthcare professional (HCP) data points and interactions, Ascend leverages a unique, agentic AI delivery platform that extends beyond the capabilities of basic chatbots. Ascend pairs fine-tuned AI agents with secure, tokenized data pipelines, where sensitive information is broken into anonymized, non-identifiable units, to amplify access to pharma resources for underserved physicians. This allows physicians to connect with a representative in real-time and access pharma resources such as samples, treatment information, order assistance, dosing calculators, and patient resources. Top pharmaceutical companies are using Ascend to amplify their field forces and provide a layer of regulated interactions with underserved HCPs. This enables faster reach for new therapies, sustained brand support, and greater engagement with previously unresponsive physicians. Ascend amplifies commercial and medical teams while keeping patient impact at the center of every interaction. "Since founding Impiricus, our mission has been to build ethical connections between pharma and physicians that ultimately help patients. Ascend gives doctors choice and relevance in how they engage, while giving pharma a responsible way to share information. The result is clearer communication, better decision-making, and more patients getting the treatments they need." said Dr. Osama Hashmi, Dermatologist, CEO and Co-founder of Impiricus Ascend has already shown strong early results across the industry. A top five pharmaceutical company used the platform to reach digitally naïve physicians for a mature brand, driving a $60 million lift in just a few months. A newly launched biotech with no field force was able to engage thousands of top-tier providers without any physical presence. Most importantly, physicians report that these connections are helping patients access critical medications faster without the time burden of the traditional pharma model. Impiricus Ascend is now available to existing and new life science partners. To learn more, send a message to [email protected]. About Impiricus Impiricus is the first and only AI-powered HCP Engagement Engine. Founded by a practicing physician and a senior pharmaceutical executive, Impiricus was created to transform how life sciences companies support physicians. We ethically connect HCPs to pharma resources, reduce go-to-market costs and accelerate patient access to the treatments they need. With our unique access to the largest opted-in network of HCPs, their insights, and clinical expertise, we are the leading provider of AI technology and real-time channels that life science companies need to deliver clear, reliable, and evidence-based resources directly into the hands of HCPs. Guided by a council of 2000+ trusted HCP advisors, we ensure every interaction is clinically meaningful, ethically grounded and leads to better patient care. Partner with us: https://impiricus.com/contact-us/ SOURCE Impiricus
Impiricus scored $3 million in a seed funding round led by FCA Venture Partners with participation from Surface Ventures for its physician virtual assistant.